Market Data
Market Cap₹12,701.42 Cr.
52W High₹2,285
Current Price₹2,076.75
52W Low₹1,336.95
Down from 52W High9.1 %
Face Value₹10
Performance
ROCE30.09 %
ROE26.65 %
EPS (TTM)₹9.83
EPS Prev Qtr₹7.41
EPS Last Year₹8.55
EBITDA Qtr₹79.89 Cr.
Book Value₹122
Financial Health
Debt/Equity0.19
Debt/Profit0.72
Total Assets₹1,205.14 Cr.
Dividend Yield0.48 %
Promoter Holding69 %
Earning Power22.79 %
Valuation
Stock P/E63.82
Industry P/E33.3
Price to Book17.01
Price to Sales8.59
Graham Number₹298.98
Key Metrics
Face Value
₹10
About Corona Remedies Ltd
Healthcare · Pharmaceuticals
Corona Remedies Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹12,701.42 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 30.09%, indicating efficient use of capital.
- ROE is at a healthy 26.65%, reflecting good return on shareholders' equity.
- The promoter holding is 69%, suggesting strong management control and alignment of interests.
- The company maintains a low debt-to-equity ratio of 0.19, indicating a conservative capital structure.
Weaknesses
- The P/E ratio of 68.29 is relatively high, suggesting the stock may be overvalued.
- The P/B ratio of 18.2 is elevated, indicating potential overvaluation in terms of book value.
- The dividend yield is low at 0.45%, which may not attract income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 361.13 | 342.42 | 353.09 | 422.43 |
| ↳ QoQ Growth | - | -5.2% | +3.1% | +19.6% |
| Expenses | 291.86 | 268.71 | 301.36 | 342.54 |
| Operating Profit | 69.27 | 73.71 | 51.73 | 79.89 |
| OPM % | 19.18% | 21.53% | 14.65% | 18.91% |
| Other Income | 2.27 | 2.24 | 4.11 | 3.15 |
| Interest | 1.93 | 1.66 | 1.38 | 2.69 |
| Depreciation | 9.2 | 9.45 | 10.29 | 13.24 |
| EBITDA | 78.47 | 83.16 | 62.02 | 93.13 |
| EBITDA Margin % | 21.73% | 24.29% | 17.56% | 22.05% |
| Profit Before Tax | 69.78 | 55.21 | 54.74 | 80.36 |
| Tax % | 25.02% | 25.25% | 17.19% | 25.2% |
| Net Profit | 52.32 | 41.27 | 45.33 | 60.11 |
| ↳ QoQ Growth | - | -21.1% | +9.8% | +32.6% |
| EPS | 8.55 | 6.75 | 7.41 | 9.83 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 61.16 | 61.16 |
| Reserves | 545.18 | 685.7 |
| Borrowings | 86.24 | 142.86 |
| Other Liabilities | 237.28 | 315.42 |
| Total Liabilities | 929.86 | 1205.14 |
| Fixed Assets | 224.58 | 553.97 |
| CWIP | 185.95 | 143.12 |
| Investments | 0.11 | 26.29 |
| Other Assets | 519.22 | 481.76 |
| Total Assets | 929.86 | 1205.14 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 229.48 |
| Cash from Investing Activity | -256.15 |
| Cash from Financing Activity | 25.28 |
| Net Cash Flow | -1.39 |
Shareholding Pattern
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters % | 69% | 69% | 69% |
| FIIs % | 1.84% | 2.25% | 3.63% |
| DIIs % | 6.77% | 7.02% | 12.9% |
| Public % | 1.36% | 0.77% | 0.89% |
| No. of Shareholders | 31,035 | 19,609 | 20,185 |
Major Shareholders (>1%)
- Ankurbhai K MehtaPromoter and Promoter Group22.00%
- Nirav Kirtikumar MehtaPromoter and Promoter Group22.00%
- Kirtikumar Laxmidas MehtaPromoter and Promoter Group20.00%
- Sepia Investments LimitedPublic Shareholding12.68%
As of 2026-06-30View all shareholders →